115909-91-6

Usage

Uses

Used in Pharmaceutical Industry:
1-CBZ-4-(2-HYDROXY-ETHYL)-PIPERIDINE is used as a key intermediate in the synthesis of drugs targeting nervous system disorders due to its potential to modulate the activity of neurotransmitters and receptors involved in these conditions.
Used in Drug Development:
1-CBZ-4-(2-HYDROXY-ETHYL)-PIPERIDINE is used as a precursor for the development of novel therapeutic agents, leveraging its chemical properties to create compounds with improved pharmacokinetics, bioavailability, and efficacy in treating neurological conditions.
Used in Chemical Synthesis:
1-CBZ-4-(2-HYDROXY-ETHYL)-PIPERIDINE is used as a versatile building block in the synthesis of new compounds with potential therapeutic effects, taking advantage of its functional groups for further chemical modifications and the creation of diverse molecular structures.
Used in Medicinal Chemistry Research:
1-CBZ-4-(2-HYDROXY-ETHYL)-PIPERIDINE is used as a subject of study in medicinal chemistry to explore its interactions with biological targets and understand its potential role in the treatment of nervous system disorders, providing insights into the design of more effective drugs.

Upstream product

• 501-53-1 benzyl chloroformate 
• 82244-11-9 ethyl-1-carbobenzoxy-Δ^4,α-piperidine-4-acetate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 

Downstream Products

• 120426-39-3 2-(N-Benzyloxycarbonylpiperidin-4-yl)ethyl iodide 
• 1242429-10-2 benzyl 4-(2-hydroxypropyl)piperidine-1-carboxylate 
• 1570178-35-6 1-{1-[(benzyloxy)carbonyl]piperidin-4-yl}propan-2-yl 5-(methylsulfonyl)-2,3-dihydro-1H-indole-1-carboxylate 
• 1354925-07-7 (S)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylthiophosphonic acid 
• 1354925-06-6 (R)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylthiophosphonic acid 
• 1354925-01-1 (S)-methyl 1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonate 
• 1354925-00-0 (R)-methyl 1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonate 
• 1354924-96-1 (S)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonic acid 
• 1354924-94-9 (R)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonic acid 
• 1354924-93-8 (S)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphinic acid 
• 1354924-88-1 (R)-1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphinic acid 
• 1354924-66-5 1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylthiophosphonic acid 
• 1354924-63-2 methyl 1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonate 
• 1354924-60-9 1-(phenylsulfonamido)-2-{4-[2-(piperidin-4-yl)ethoxy]benzamido}ethylphosphonic acid 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

ESTROGEN RECEPTOR DEGRADING PROTACS

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R6, R7, R8, Linker, A, G, D and E have a

NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF

The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Tailoring of integrin ligands: Probing the charge capability of the metal ion-dependent adhesion site

Intervention in integrin-mediated cell adhesion and integrin signaling pathways is an ongoing area of research in medicinal chemistry and drug development. One key element in integrin-ligand interaction is the coordination of the bivalent cation at the me

MODULATORS OF TOLL-LIKE RECEPTORS

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.